non-Hodgkins lymphomachildren and adolescentstargeted therapyrituximab (Mabthera)неходжкинские лимфомыдети и подросткитаргетная терапияритуксимаб (Мабтера)РНПЦ ДОГИ, Минск, Беларусь; Онкодиспансер Московской области, Балашиха; РДКБ, Махачкала; ОДКБ № 1, Екатеринбург; ОДКБ, Иркутск; РДКБ, Москва; ОДКБ, Нижний Новгород; Пермская КДКБ, Пермь; ГКБ № 31, Санкт-Петербург; РДКБ, ­Казань; РДКБ Чебоксары; ОДКБ, Челябинск; АДКБ ­Архангельск; ОКДБ, Нижневартовск; ОДКБ, Рязань; ГБУЗ ОДБ, Брянск; А.Е. Руднева и Ю.В. Румянцева1.1. Murphy S.B., Bowman W.P., Abromowitch M. et al. Results of treatment of advanced – stage Burkitt, s lymphoma and B-cell (sIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated highdose methotrexate and cytarabine. J Clin Oncol 1986;4(12):1732–9.Murphy S.B., Bowman W.P., Abromowitch M. et al. Results of treatment of advanced – stage Burkitt, s lymphoma and B-cell (sIg+) acute lymphoblastic leukemia with high-dose fractionated cyclophosphamide and coordinated highdose methotrexate and cytarabine. J Clin Oncol 1986;4(12):1732–9.2.2. Patte C., Philip T., Rodary C. et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9(1):123–32.Patte C., Philip T., Rodary C. et al. High survival rate in advanced-stage B-cell lymphomas and leukemias without CNS involvement with a short intensive polychemotherapy: results from the French Pediatric Oncology Society of a randomized trial of 216 children. J Clin Oncol 1991;9(1):123–32.3.3. Reiter A., Schrappe M., Parwaresch R. et al. Non-Hodgkin, s lymphomas of childhood and adolescents: results of a treatment stratified for biologic subtypes and stage – a report of the BFM Group. J Clin Oncol 1995;13:359–72.Reiter A., Schrappe M., Parwaresch R. et al. Non-Hodgkin, s lymphomas of childhood and adolescents: results of a treatment stratified for biologic subtypes and stage – a report of the BFM Group. J Clin Oncol 1995;13:359–72.4.4. Самочатова Е.В., Алейникова О.В., Беликова Л.Ю. и др. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии; по данным клиник России и Беларуси. Гематология и трансфузиология 2001;(1):3–10. [Samochatova E.V., Aleynikova O.V., Belikova L.Yu. et al. Non-Hodgkin lymphomas in children: clinical characteristics, possibilities of diagnosis and therapy according to data of Russian and Belarus clinics. Gematologia i transfusiologia = Hematology and Transfusiology 2001;(1):3–10. (In Russ.)].Самочатова Е.В., Алейникова О.В., Беликова Л.Ю. и др. Неходжкинские лимфомы у детей: клиническая характеристика, возможности диагностики и терапии; по данным клиник России и Беларуси. Гематология и трансфузиология 2001;(1):3–10. [Samochatova E.V., Aleynikova O.V., Belikova L.Yu. et al. Non-Hodgkin lymphomas in children: clinical characteristics, possibilities of diagnosis and therapy according to data of Russian and Belarus clinics. Gematologia i transfusiologia = Hematology and Transfusiology 2001;(1):3–10. (In Russ.)].5.5. Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346(4):235–42.Coiffier B., Lepage E., Briere J. et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346(4):235–42.6.6. Pfreundshuh M.G.M., Kuhnt E., Trümper L. et al. Randomized intergroup trial of first-line treatment for patients < 61 years with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab – early stopping after first interim analysis. Blood 2002;11:A65.Pfreundshuh M.G.M., Kuhnt E., Trümper L. et al. Randomized intergroup trial of first-line treatment for patients < 61 years with diffuse large B-cell lymphoma (DLBCL) with a CHOP-like regimen with and without the anti-CD20 antibody rituximab – early stopping after first interim analysis. Blood 2002;11:A65.7.7. Samochatova E., Myakova N., Shelikhova L. et al. Preliminary results of treatment of pediatric advance-staged mature B-cell NHL/B-ALL with intensive chemotherapy + rituximab: effectiveness and toxicity. Pediatric Blood and Cancer 2006;46(7):854–5.Samochatova E., Myakova N., Shelikhova L. et al. Preliminary results of treatment of pediatric advance-staged mature B-cell NHL/B-ALL with intensive chemotherapy + rituximab: effectiveness and toxicity. Pediatric Blood and Cancer 2006;46(7):854–5.8.8. Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-FrankfurtMunster Group Trial NHL-BFM-90. Blood 1999;94(10):3294–306.Reiter A., Schrappe M., Tiemann M. et al. Improved treatment results in childhood B-cell neoplasms with tailored intensification of therapy: a report of the Berlin-FrankfurtMunster Group Trial NHL-BFM-90. Blood 1999;94(10):3294–306.9.9. Non-Hodgkin, s lymphomas, Ed. by I.T. Magrath. Berlin: Edwards, 1990.Non-Hodgkin, s lymphomas, Ed. by I.T. Magrath. Berlin: Edwards, 1990.10.10. Samochatova E.V., Maschan A.A., Shelikhova L.N. et al. Therapy of advancedstage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol 2014;36(5):395–401.Samochatova E.V., Maschan A.A., Shelikhova L.N. et al. Therapy of advancedstage mature B-cell lymphoma and leukemia in children and adolescents with rituximab and reduced intensity induction chemotherapy (B-NHL 2004M protocol): the results of a multicenter study. J Pediatr Hematol Oncol 2014;36(5):395–401.11.11. Horn H., Zipert M., Becher C. et al. MYC status in concept with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121(12):2253–63.Horn H., Zipert M., Becher C. et al. MYC status in concept with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma. Blood 2013;121(12):2253–63.12.12. Dave S.S., Fu K., Wright G.W. et al. Molecular diagnosis of Burcitt, s lymphoma. N Engl J Med 2006;354 (23):2431–42.Dave S.S., Fu K., Wright G.W. et al. Molecular diagnosis of Burcitt, s lymphoma. N Engl J Med 2006;354 (23):2431–42.13.13. Aukema M., Thiel L., Rohde M. et al. Sequential karyotyping in Burkitt lymphoma reveals a linearal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol 2015;170(6):814–25.Aukema M., Thiel L., Rohde M. et al. Sequential karyotyping in Burkitt lymphoma reveals a linearal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations. Br J Haematol 2015;170(6):814–25.